Tobacco remains the leading preventable cause of death in the United States, and disproportionately affects people with serious mental illness. E-cigarette use is increasing in the United States and people with mental illness are reporting use that is greater than the general population. This webinar will summarize tobacco use among those with mental illness, discuss e-cigarettes, and summarize the most recent recommendations on risks and safety. Currently, there are seven FDA-approved medications for tobacco cessation (nicotine replacement therapies (gums, patches, lozenges, inhaler, nasal spray), bupropion and varenicline. When medications are combined with psychosocial treatments such as a tobacco cessation group, individual therapy or a structured tobacco cessation program, quit rates from tobacco can rise up to nearly 40% or higher.
Access “Tobacco and the Emergence of E-Cigarettes: Addressing the Unmet Needs in Mental Health” at: https://pcssnow.org/event/tobacco-and-the-emergence-of-e-cigarettes-addressing-the-unmet-needs-in-mental-health/